Niopam (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑ray photons. When injected, it distributes within the vascular or joint spaces, increasing X‑ray attenuation in those areas. This creates a contrast difference between enhanced structures and surrounding tissues, allowing better radiographic differentiation.

The dose of Niopam is determined by the prescribing physician based on the specific imaging study, patient weight, renal function, and the required level of contrast enhancement. Healthcare professionals calculate the appropriate volume and concentration for each individual case.

The safety of Niopam in pregnancy and lactation has not been fully established. It should be used only when clearly needed and after weighing the potential benefits against possible risks. Clinicians should consult current guidelines and consider alternative imaging methods when possible.

To order Niopam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Niopam (Iopamidol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality while reducing the incidence of discomfort and adverse reactions, making it a preferred choice for many diagnostic procedures.

Niopam should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze or shake the vial before use.

Niopam is supplied as a sterile solution for injection and is administered intravenously, intra‑arterially, or intra‑articularly by a qualified healthcare professional. The injection rate and volume are tailored to the specific imaging protocol and patient characteristics.

The most serious risks include severe allergic reactions such as anaphylaxis, acute renal impairment, especially in patients with pre‑existing kidney disease, and cardiovascular events like hypotension or arrhythmias. Prompt recognition and management of these reactions are essential.

Niopam is contraindicated in patients with a known hypersensitivity to Iopamidol or any iodinated contrast media, those with uncontrolled severe renal insufficiency, and individuals who have experienced severe reactions to previous contrast agents. Clinicians should assess each patient’s medical history before use.